Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 10/2014

01.10.2014 | Current Opinion

Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary

verfasst von: Robin Gauld

Erschienen in: PharmacoEconomics | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

New Zealand’s Pharmaceutical Management Agency (Pharmac) was created in 1993. Unusual in international terms, Pharmac’s objective is to work within a fixed budget while ensuring the New Zealand public receives an adequate range of government-subsidised medicines. Following its 20th anniversary, this article reflects on Pharmac’s development and role within the New Zealand health system, various changes over time to the agency’s scope and activities, its performance and its present challenges.
Literatur
1.
Ragupathy R, Aaltonen K, Tordoff J, Norris P, Reith D. A three-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics. 2012;30(11):1051–65.PubMedCrossRef
2.
Gauld R. Revolving doors: New Zealand’s health reforms: the Saga continues. Wellington: Institute of Policy Studies and Health Services Research Centre; 2009.
3.
Gauld R. New Zealand’s post-2008 health system reforms: toward re-centralization of organizational arrangements. Health Policy. 2012;106:110–3.PubMedCrossRef
4.
Clark H. Pharmaceutical costs and regulation: from the Minister’s desk. In: Davis P, editor. For health or profit? Medicine, the pharmaceutical industry, and the state in New Zealand. Auckland: Oxford University Press; 1992. p. 53–74.
5.
Wilson JQ. Bureaucracy: what government agencies do and why they do it. New York: Basic Books; 1989.
6.
Pharmaceutical Management Agency. Pharmac’s decision criteria: consultation document. Wellington: Pharmaceutical Management Agency; 2013.
7.
Grocott R. Applying programme budgeting marginal analysis in the health sector: 12 years of experience. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):181–7.PubMedCrossRef
8.
Grocott R, Metcalfe S, Alexander P, Werner R. Assessing the value for money of pharmaceuticals in New Zealand: Pharmac’s approach to cost-utility analysis. N Z Med J. 2013;126(1378):60–73.PubMed
9.
Goldacre B. Bad pharma: how drug companies mislead doctors and harm patients. London: Fourth Estate; 2012.
10.
Milne R, Wonder M. Response to Pharmac on access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1347):91–3.PubMed
11.
Rasiah D, Edwards R, Crampton P. Funding community medicines by exception: a descriptive epidemiological study from New Zealand. N Z Med J. 2012;125(1350):21–9.PubMed
12.
Coyle G. How does the operation of Pharmac’s ‘Community Exceptional Circumstances’ policy align with the distributive justice principles of fairness and equity as described by John Rawls and Amartya Sen? Auckland University of Technology PhD thesis; 2012.
13.
Manning J. Exceptional circumstances schemes and the social factors exclusion in healthcare rationing. Oxford Univ Commonwealth Law J. 2013;13(1):75–114.CrossRef
14.
Tordoff J, Norris P, Reith D. ‘Price management’ and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand. Value Health. 2008;11(7):1214–26.PubMedCrossRef
15.
OECD. Health at a Glance 2013. Paris: OECD; 2013.
16.
Pharmaceutical Management Agency. Pharmaceutical Management Agency. Annual Review 2013. Wellington: Pharmaceutical Management Agency; 2013.
17.
OECD. OECD Health Data. Paris: OECD; 2013.
18.
The US health system in perspective: a comparison of twelve industrialized nations. New York: Commonwealth Fund; 2011.
19.
Cobiac L. Pharmac looks great value for money: an Australian perspective. N Z Med J. 2012;125(1358):82–3.PubMed
20.
Duckett S, Breadon P, Ginnivan L, Venkararaman P. Australia’s bad drug deal: high pharmaceutical prices. Melbourne: Grattan Institute; 2013.
21.
Fenton E. Making fair funding decisions for high cost cancer care: the case of herceptin in New Zealand. Public Health Ethics. 2010;3(2):137–46.CrossRef
22.
Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1346):12–28.PubMed
23.
Moodie P, Metcalfe S, Poynton M. Do pharmaceutical score cards give us the answers we seek? N Z Med J. 2011;124(1346):69–74.PubMed
24.
Cumming J, Mays N, Daube J. How New Zealand has contained expenditure on drugs. BMJ. 2010;340(c2441):1224–7.
25.
Begg E, Sidwell A, Gardiner S, Nicholls G, Scott R. The sorry saga of the statins in New Zealand: pharmacopolitics versus patient care. N Z Med J. 2003;116(1170):U360.PubMed
26.
Ellis CJ, White H. Pharmac and the statin debacle. N Z Med J. 2006;119(1236).
27.
Moodie P, Dougherty S, Metcalfe S. Pharmac and statins: getting the best population health gains. N Z Med J. 2006;119(1238):1–3.
28.
Gleeson D, Lopert R, Reid P. How the Trans Pacific Partnership Agreement could undermine Pharmac and threaten access to affordable medicines and health equity in New Zealand. Health Policy. 2013;112:227–33.PubMedCrossRef
29.
Davis P. Tough but fair? The active management of the New Zealand Drug Benefits Scheme by an independent crown agency. Aust Health Rev. 2004;28(2):171–81.PubMedCrossRef
Metadaten
Titel
Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary
verfasst von
Robin Gauld
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 10/2014
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0178-2

Weitere Artikel der Ausgabe 10/2014

PharmacoEconomics 10/2014 Zur Ausgabe

Review Article

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility

Practical Application

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models

Original Research Article

Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes

Leading Article

Reconceptualising the External Validity of Discrete Choice Experiments

Letter to the Editor

Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary”

Erratum

Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider